J0576 HCPCS Level II code: Injection, buprenorphine extended-release (brixadi), 1 mg
CMS terminated J0576: its last date of service was Mar 31, 2024. It stays here for looking up older claims; newer services need a current code.
Official description
J0576Injection, buprenorphine extended-release (brixadi), 1 mg
Short description: Inj buprenorph (brixadi) 1mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J0576 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2024
- Terminated after
- Mar 31, 2024
Where J0576 sits
- 1J codesDrugs administered other than orally
- 2Terminated J0576Injection, buprenorphine extended-release (brixadi), 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code J0576 still valid?
No. CMS terminated J0576; its last date of service was Mar 31, 2024. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover J0576?
CMS lists J0576’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0576
All J codesJ0570Buprenorphine implant, 74.2 mgJ0571Buprenorphine, oral, 1 mgJ0572Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphineJ0573Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphineJ0574Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphineJ0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphineJ0577Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapyJ0578Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapyJ0582Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mgJ0583Injection, bivalirudin, 1 mgJ0584Injection, burosumab-twza 1 mgJ0585Injection, onabotulinumtoxina, 1 unit